Your session is about to expire
← Back to Search
Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings
N/A
Waitlist Available
Led By Stephen J Bartels, MD, MS
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the outcome will be measured 3 months after intervention implementation.
Awards & highlights
No Placebo-Only Group
Summary
This trial will help create a package of interventions to reduce the spread of COVID-19 and other infectious diseases among staff and people with mental illness and developmental disabilities who live in congregate settings.
Eligible Conditions
- Intellectual Disability
- Axis I Disorder
- Coronavirus
- Developmental Disability
- Mental Health Disorders
- Coronavirus Infection
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ the outcome will be measured 3 months after intervention implementation.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the outcome will be measured 3 months after intervention implementation.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Best Practices Fidelity at 12 Months
Best Practices Fidelity at 15 Months
Best Practices Fidelity at 3 Months
+9 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Tailored Best Practices (TBP)Experimental Treatment1 Intervention
The \~200 group homes randomized into this arm will receive the Tailored Best Practices (TBP) intervention package as part of routine training activities. TBP consists of COVID-19 mitigation measures specifically adapted for staff and residents with SMI and ID/DD in congregate living settings. Sites in this arm will receive coaching specific to the setting, staff, and residents.
Group II: Generic Best Practices (GBP)Active Control1 Intervention
The \~200 group homes randomized into this arm will receive the Generic Best Practices (GBP) intervention package as part of routine training activities. GBP consists of state and federal standard guidelines for COVID-19 mitigation for all congregate living settings.
Find a Location
Who is running the clinical trial?
Dartmouth CollegeOTHER
86 Previous Clinical Trials
1,414,386 Total Patients Enrolled
Vinfen CorporationUNKNOWN
1 Previous Clinical Trials
240 Total Patients Enrolled
Massachusetts General HospitalLead Sponsor
3,024 Previous Clinical Trials
13,408,415 Total Patients Enrolled
1 Trials studying Intellectual Disability
280 Patients Enrolled for Intellectual Disability
Patient-Centered Outcomes Research InstituteOTHER
577 Previous Clinical Trials
27,074,543 Total Patients Enrolled
3 Trials studying Intellectual Disability
1,506 Patients Enrolled for Intellectual Disability
AdvocatesUNKNOWN
North Suffolk Mental Health AssociationOTHER
16 Previous Clinical Trials
687 Total Patients Enrolled
Riverside Community Care, Inc.UNKNOWN
Bay Cove Human ServicesUNKNOWN
2 Previous Clinical Trials
2,065 Total Patients Enrolled
Open Sky Community ServicesUNKNOWN
Stephen J Bartels, MD, MSPrincipal InvestigatorMassachusetts General Hospital
2 Previous Clinical Trials
330 Total Patients Enrolled